Skip to main content
Year archive

Genmab — 2023 filings

All 149 regulatory filings released by Genmab (GMAB) in 2023, sourced directly from the official regulator.

149 Filings
2023 Period
2023 filings (149)
Filing Released Lang
6-K
Foreign Filer Report
2023-12-13 English
6-K
Foreign Filer Report
2023-12-06 English
Share Issue/Capital Change 2023
Share Issue/Capital Change
2023-12-05 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2023-12-05 Danish
6-K
Foreign Filer Report
2023-12-01 English
6-K
Foreign Filer Report
2023-11-21 English
Director's Dealing 2023
Director's Dealing
2023-11-21 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2023-11-21 English
6-K
Foreign Filer Report
2023-11-09 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-09 English
Major Shareholder Announcement
Major Shareholding Notification
2023-11-09 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-08 English
Major Shareholder Announcement
Major Shareholding Notification
2023-11-08 English
6-K
Foreign Filer Report
2023-11-08 English
6-K
Foreign Filer Report
2023-11-07 English
6-K
Foreign Filer Report
2023-10-17 English
Earnings Release 2023
Earnings Release Q3 2023
2023-10-17 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
Earnings Release Q3 2023
2023-10-17 English
6-K
Foreign Filer Report
2023-10-05 English
6-K
Foreign Filer Report
2023-09-28 English
6-K
Foreign Filer Report
2023-09-25 English
Legal Proceedings Report 2023
Legal Proceedings Report
2023-09-25 English
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Regulatory Filings
2023-09-25 English
6-K
Foreign Filer Report
2023-09-13 English
6-K
Foreign Filer Report
2023-09-12 English
Share Issue/Capital Change 2023
Share Issue/Capital Change
2023-09-12 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2023-09-12 English
6-K
Foreign Filer Report
2023-09-05 English
Regulatory Filings 2023
Regulatory Filings
2023-09-04 English
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
Regulatory Filings
2023-09-04 English
6-K
Foreign Filer Report
2023-08-16 English
6-K
Foreign Filer Report
2023-08-15 English
Share Issue/Capital Change 2023
Share Issue/Capital Change
2023-08-15 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2023-08-15 English
6-K
Foreign Filer Report
2023-08-03 English
Earnings Release 2023
Earnings Release H1 2023
2023-08-03 English
Genmab Announces Financial Results for the First Half of 2023
Interim / Quarterly Report H1 2023
2023-08-03 English
6-K
Foreign Filer Report
2023-07-28 English
Earnings Release 2023
Earnings Release H1 2023
2023-07-28 English
Genmab Updates 2023 Financial Guidance
Earnings Release H1 2023
2023-07-28 English
6-K
Foreign Filer Report
2023-07-21 English
Regulatory Filings 2023
Regulatory Filings
2023-07-21 English
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Regulatory Filings
2023-07-21 Danish
6-K
Foreign Filer Report
2023-07-20 English
Earnings Release 2023
Earnings Release Q2 2023
2023-07-20 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
Earnings Release Q2 2023
2023-07-20 Danish
6-K
Foreign Filer Report
2023-06-28 English
Earnings Release 2023
Earnings Release Q2 2023
2023-06-28 English
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Regulatory Filings
2023-06-28 English
6-K
Foreign Filer Report
2023-06-21 English
6-K
Foreign Filer Report
2023-06-20 English
Capital/Financing Update 2023
Capital/Financing Update
2023-06-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2023-06-20 English
6-K
Foreign Filer Report
2023-06-20 English
6-K
Foreign Filer Report
2023-06-08 English
6-K
Foreign Filer Report
2023-06-01 English
Director's Dealing 2023
Director's Dealing
2023-06-01 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2023-06-01 English
6-K
Foreign Filer Report
2023-05-31 English
Director's Dealing 2023
Director's Dealing
2023-05-31 English
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
Director's Dealing
2023-05-31 English
6-K
Foreign Filer Report
2023-05-24 English
6-K
Foreign Filer Report
2023-05-23 English
Share Issue/Capital Change 2023
Share Issue/Capital Change
2023-05-23 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2023-05-23 Danish
6-K
Foreign Filer Report
2023-05-19 English
Regulatory Filings 2023
Regulatory Filings
2023-05-19 English
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLB
Regulatory Filings
2023-05-19 English
6-K
Foreign Filer Report
2023-05-10 English
6-K
Foreign Filer Report
2023-04-24 English
Legal Proceedings Report 2023
Legal Proceedings Report
2023-04-24 English
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Legal Proceedings Report
2023-04-24 English
6-K
Foreign Filer Report
2023-04-21 English
Legal Proceedings Report 2023
Legal Proceedings Report
2023-04-21 English
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Regulatory Filings
2023-04-21 English
6-K
Foreign Filer Report
2023-04-18 English
Earnings Release 2023
Earnings Release Q1 2023
2023-04-18 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
Earnings Release Q1 2023
2023-04-18 English
6-K
Foreign Filer Report
2023-04-06 English
Director's Dealing 2023
Director's Dealing
2023-04-06 English
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Director's Dealing
2023-04-06 English
6-K
Foreign Filer Report
2023-04-03 English
Remuneration Information 2023
Remuneration Information
2023-04-03 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2023-04-03 English
6-K
Foreign Filer Report
2023-04-03 English
Regulatory Filings 2023
Regulatory Filings
2023-04-03 English
Completion of share buy-back program
Transaction in Own Shares
2023-04-03 English
Completion of share buy-back program
Transaction in Own Shares
2023-04-03 English
6-K
Foreign Filer Report
2023-04-03 English
6-K
Foreign Filer Report
2023-03-29 English
Director's Dealing 2023
Director's Dealing
2023-03-29 English
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Director's Dealing
2023-03-29 English
6-K
Foreign Filer Report
2023-03-29 English
6-K
Foreign Filer Report
2023-03-27 English
Transaction in Own Shares 2023
Transaction in Own Shares
2023-03-27 English
Transactions in connection with share buy-back program
Regulatory Filings
2023-03-27 Danish
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-03-27 English
6-K
Foreign Filer Report
2023-03-20 English
Transaction in Own Shares 2023
Transaction in Own Shares
2023-03-20 English
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-03-20 English
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-03-20 English
6-K
Foreign Filer Report
2023-03-13 English
Regulatory Filings 2023
Regulatory Filings
2023-03-13 English
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-03-13 English
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-03-13 Danish
Transaction in Own Shares 2023
Transaction in Own Shares
2023-03-13 English
Transactions in connection with share buy-back program
Regulatory Filings
2023-03-13 Danish
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-03-13 Danish
6-K
Foreign Filer Report
2023-03-06 English
Transaction in Own Shares 2023
Transaction in Own Shares
2023-03-06 English
Transactions in connection with share buy-back program
Regulatory Filings
2023-03-06 Danish
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-03-06 English
6-K
Foreign Filer Report
2023-03-01 English
6-K
Foreign Filer Report
2023-02-28 English
Share Issue/Capital Change 2023
Share Issue/Capital Change
2023-02-28 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2023-02-28 English
6-K
Foreign Filer Report
2023-02-28 English
6-K
Foreign Filer Report
2023-02-27 English
Regulatory Filings 2023
Regulatory Filings
2023-02-27 English
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-02-27 English
Transactions in connection with share buy-back program
Transaction in Own Shares
2023-02-27 Danish
6-K
Foreign Filer Report
2023-02-24 English
Director's Dealing 2023
Director's Dealing
2023-02-24 English
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Director's Dealing
2023-02-24 Danish
6-K
Foreign Filer Report
2023-02-23 English
6-K
Foreign Filer Report
2023-02-22 English
Director's Dealing 2023
Director's Dealing
2023-02-22 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2023-02-22 English
20-F
Annual Report FY 2022
2023-02-22 English
6-K
Foreign Filer Report
2023-02-22 English
6-K
Foreign Filer Report
2023-02-22 English
Transaction in Own Shares 2023
Transaction in Own Shares
2023-02-22 English
Genmab Announces Initiation of Share Buy-Back Program
Transaction in Own Shares
2023-02-22 Danish
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-02-22 English
Report Publication Announcement 2023
Report Publication Announcement
2023-02-22 English
Genmab Publishes 2022 Annual Report
Annual Report FY 2022
2023-02-22 English
SEC SCHEDULE 13G
Major Shareholding Notification
2023-02-06 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-31 English
6-K
Foreign Filer Report
2023-01-30 English
6-K
Foreign Filer Report
2023-01-24 English
6-K
Foreign Filer Report
2023-01-24 English
Earnings Release 2022
Earnings Release FY 2022
2023-01-24 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Earnings Release FY 2022
2023-01-24 Danish
6-K
Foreign Filer Report
2023-01-19 English
Director's Dealing 2023
Director's Dealing
2023-01-19 English
Correction to Company Announcement No. 1 of January 3, 2023
Director's Dealing
2023-01-19 English
6-K
Foreign Filer Report
2023-01-03 English
Director's Dealing 2023
Director's Dealing
2023-01-03 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2023-01-03 English